The effectiveness of Mexidol® in patients with neurological complications of type 2 diabetes

Author:
E.L. PUGACHEVA

FSBEI in "First St. Petersburg State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia, St. Petersburg, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2022, Vol. 122, No. 5

Abstract:
Objective of the study. To study the leading pathogenetic mechanisms underlying the development of complications of type 2 diabetes mellitus (DM) and to optimize therapeutic approaches to the treatment of this category of patients. Material and methods. The article presents the results of treatment of 30 patients suffering from type 2 DM and its complications who received Mexidol intravenously by drip at 500 mg / day for 14 days, with a subsequent transition to oral administration of Mexidol FORTE 250 at 250 mg 3 times a day for 60 days. The dynamics of the condition was assessed using standardized neuropsychological scales. Clinical and biochemical studies were performed according to the protocol for the management of patients with type 2 DM. Results.Mexidol therapy according to the presented regimen was accompanied by improved cognitive functions, a decrease in signs of asthenia, anxiety and depression, normalization of sleep, improvement in blood biochemical parameters, and an increase in the quality of life. Conclusion. Prescribing Mexidol as a sequential, long-term therapy may prove to be an effective approach for improving the quality of life of patients with type 2 diabetes. Key words: diabetes mellitus, hypoxia, oxidative stress, antioxidants, neurotransmitters, antihypoxants, Mexidol.